EL.EN.
7.9.2022 08:21:35 CEST | Business Wire | Press release
Thanks to the El.En. Group of Calenzano, Florence, a multinational specialized in laser production for medical and industrial applications, and for conservation of artistic heritage, an event was organized to celebrate the just over 40 years since it was founded in the presence of the 2018 Nobel Prize winner for Physics, Gérard Mourou, and other prominent professors of international acclaim who contributed to pioneering research in the field of laser physics, paving the way for a multitude of scientific and medical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005326/en/
G.Mourou, O.Svelto and P.Salvadeo special guest stars at El.En. exclusive event (Photo: Business Wire)
The event was also held to honor two shining stars in the world of physics: The Nobel prize winner Gérard Mourou, who, thanks to the General Manager of El.En., Mr. Paolo Salvadeo, was given the prestigious honor of receiving the Key to the City of Florence from the Mayor of Florence in a separate public ceremony in the afternoon, and Orazio Svelto, Professor Emeritus of Polytechnic of Milan, father of laser in Italy. Prof. Svelto invented the so-called “hollow fiber compressor” making it possible to achieve laser impulses lasting attoseconds, with previously unimaginable peak power. This system is currently used in many laboratories the world over conducting cutting edge scientific research and non-linear spectroscopy.
During the gala dinner in the Salone dei Cinquecento of Palazzo Vecchio, in the presence of the major political authorities, the director of the Uffizi Gallery, of Console USA, and other institutional personalities and of the world of laser, Prof. Mourou shared his vision of the future of science, starting with the studies that earned him his Nobel prize for inventing the so-called Chirped Pulse Amplification (CPA), developed in collaboration with Donna Theo Strickland. It is a technique that, thanks to the generation of ultra-brief and high intensity impulses, has made laser even more versatile and enabled exploration of previously unknown dynamics of physics. A notable presence at the gala dinner was Prof. Sune Svamberg, who for many years was on the Nobel Committee for Physics, two years during which he was president, and Prof. Ursula Keller, one of the most acclaimed and well-known scientists in the world in the field of optoelectronics and photonics.
“It’s an honor and I take great pride in being able to create and maintain a deep connection between the world of academics and industry. This shows how crucial collaboration is between these worlds to conduct studies and make discoveries that improve the people’s quality of life. An osmosis of knowledge and a continuous and stimulating dialog that mark continuity among professors and alumni, many of whom dedicate their daily lives in the company laboratories of our group,” affirmed Paolo Salvadeo, General Manager of the El.En. Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005326/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
